Bioxcel Therapeutics is a biopharmaceutical company focused on innovative drug development to address unmet medical needs in the fields of neurology and psychiatry
Utilizing its proprietary artificial intelligence platform, the company aims to identify and advance novel therapeutics that can improve patient outcomes in challenging conditions such as agitation in Alzheimer's patients and cancer-related symptoms. Bioxcel's approach integrates data-driven decision-making and clinical research to bring forth potential treatments that enhance the quality of life for patients dealing with complex health issues.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrated favorable safety and efficacy in reducing agitation symptoms.
From no AI category losses in February, to 3 drops in March - now all 7 fell this week, clearly indicating that that the surge in AI stock prices that began back on October 31st is, indeed, over.
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial intelligence technology sector is slowing.
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
BioXcel Therapeutics shares surge 25.1% as the company terminates its proposed public offering and shifts focus to upcoming FDA meeting and Phase 3 trial.
